Blueprint Medicines Ownership | Who Owns Blueprint Medicines?


OverviewForecastRevenueFinancialsChartTranscripts

Blueprint Medicines Ownership Summary


Blueprint Medicines is owned by 101.09% institutional investors, 0.88% insiders. Vanguard group is the largest institutional shareholder, holding 10.69% of BPMC shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 3.23% of its assets in Blueprint Medicines shares.

BPMC Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockBlueprint Medicines101.09%0.88%-1.97%
SectorHealthcare Stocks 486.50%11.08%-397.59%
IndustryBiotech Stocks 304.14%11.08%-215.23%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Vanguard group6.77M10.69%$590.91M
Blackrock6.65M10.58%$716.45M
Blackrock funding, inc. /de6.12M9.62%$784.26M
Price t rowe associates inc /md/5.68M8.96%$495.33M
Wellington management group llp4.28M6.75%$373.42M
Pentwater capital management lp3.90M6.13%$499.90M
State street2.50M3.94%$218.07M
Fmr2.25M3.55%$196.04M
Fil1.76M2.77%$225.53M
Ubs oconnor1.71M2.69%$219.65M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Syquant capital sas805.60K34.24%$103.26M
Aquilo capital management83.93K13.32%$7.43M
Ubs oconnor1.71M11.25%$219.65M
Twin securities120.13K8.74%$15.40M
Trium capital llp240.10K7.66%$30.78M
Alpine associates management1.06M7.25%$135.91M
Glazer capital1.33M6.10%$170.65M
Dafna capital management168.76K5.97%$21.63M
Kryger capital248.22K5.89%$31.82M
Chicago capital management60.00K5.65%$7.69M

Top Buyers

HolderShares% AssetsChange
Pentwater capital management lp3.90M3.24%3.90M
Fil1.76M0.19%1.76M
Ubs oconnor1.71M11.25%1.70M
Glazer capital1.33M6.10%1.33M
Alpine associates management1.06M7.25%1.06M

Top Sellers

HolderShares% AssetsChange
Avoro capital advisors375.00K0.84%-3.48M
Fmr2.25M0.01%-2.27M
William blair investment management8.57K0.00%-1.42M
T. rowe price investment management---1.30M
Alkeon capital management---900.63K

New Positions

HolderShares% AssetsChangeValue
Pentwater capital management lp3.90M3.24%3.90M$499.90M
Fil1.76M0.19%1.76M$225.53M
Glazer capital1.33M6.10%1.33M$170.65M
Alpine associates management1.06M7.25%1.06M$135.91M
Davidson kempner capital management lp1.04M2.19%1.04M$132.68M

Sold Out

HolderChange
Tfc financial management-1.00
National bank of canada /fi/-1.00
Td private client wealth-2.00
American capital advisory-3.00
Quadrant capital group-3.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20253741.63%64,295,614-6.16%1010.87%2065.10%114-0.87%
Mar 31, 202519-94.78%3,679,558-94.53%50.05%12-94.15%5-95.05%
Dec 31, 20243625.23%67,270,9263.92%1061.02%2022.02%10221.43%
Sep 30, 20243393.04%64,638,237-2.28%1010.92%19617.37%83-17.82%
Jun 30, 20243297.17%66,148,2281.60%1050.94%1678.44%1019.78%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv2.09M3.23%39.02K
Vanguard US Total Market Shares ETF2.00M3.13%1.81K
iShares Russell 2000 ETF1.60M2.47%11.11K
Vanguard Small Cap Index1.58M2.44%-33.77K
Vanguard Health Care Inv1.36M2.11%-727.09K
Vanguard Institutional Extnd Mkt Idx Tr996.08K1.54%306.00
Delaware Small Cap Core I908.17K1.43%-5.63K
Vanguard Small Cap Growth Index Inv885.23K1.37%-2.86K
JPMorgan Growth Advantage A770.25K1.19%-4.80K
T. Rowe Price Integrated US SmCapGrEq734.32K1.16%367.16K

Recent Insider Transactions


DateNameRoleActivityValue
Jul 03, 2025Rossi Christina CHIEF OPERATING OFFICERSell$150.31K
Jul 03, 2025Carter Percy H. CHIEF SCIENTIFIC OFFICERSell$134.79K
Jun 03, 2025Carter Percy H. CHIEF SCIENTIFIC OFFICERSell$30.82K
Jun 03, 2025Carter Percy H. CHIEF SCIENTIFIC OFFICERSell$309.21K
May 27, 2025Albers Jeffrey W.-Sell$439.44K

Insider Transactions Trends


DateBuySell
2025 Q2-18
2025 Q1-32
2024 Q4-18
2024 Q3-6
2024 Q2-21

BPMC Ownership FAQ


Who Owns Blueprint Medicines?

Blueprint Medicines shareholders are primarily institutional investors at 101.09%, followed by 0.88% insiders and -1.97% retail investors. The average institutional ownership in Blueprint Medicines's industry, Biotech Stocks , is 304.14%, which Blueprint Medicines falls below.

Who owns the most shares of Blueprint Medicines?

Blueprint Medicines’s largest shareholders are Vanguard group (6.77M shares, 10.69%), Blackrock (6.65M shares, 10.58%), and Blackrock funding, inc. /de (6.12M shares, 9.62%). Together, they hold 30.89% of Blueprint Medicines’s total shares outstanding.

Does Blackrock own Blueprint Medicines?

Yes, BlackRock owns 10.58% of Blueprint Medicines, totaling 6.65M shares as of Jun 2024. This represents 0.02% of BlackRock's total assets, with a market value of 716.45M$. In the last quarter, BlackRock increased its holdings by 199.84K shares, a 3.10% change.

Who is Blueprint Medicines’s biggest shareholder by percentage of total assets invested?

Syquant capital sas is Blueprint Medicines’s biggest shareholder by percentage of total assets invested, with 34.24% of its assets in 805.6K Blueprint Medicines shares, valued at 103.26M$.

Who is the top mutual fund holder of Blueprint Medicines shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Blueprint Medicines shares, with 3.23% of its total shares outstanding invested in 2.09M Blueprint Medicines shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools